GSK plc has entered a collaboration with Hengrui Pharma to develop up to 12 innovative medicines, including a PDE3/4 inhibitor for COPD, with GSK paying $500 million upfront and potential future payments totaling around $12 billion. This filing is significant and shows a positive sentiment for equity investors.